---
title: "H.C. Wainwright Remains a Buy on Crispr Therapeutics AG (CRSP)"
description: "According to TipRanks, Kapoor is a 3-star analyst with an average return of 3.5% and a 43.81% success rate. Kapoor covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Haloz"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/262269483.md"
published_at: "2025-10-22T14:25:29.000Z"
---

# H.C. Wainwright Remains a Buy on Crispr Therapeutics AG (CRSP)

> According to TipRanks, Kapoor is a 3-star analyst with an average return of 3.5% and a 43.81% success rate. Kapoor covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Halozyme, and Sarepta Therapeutics. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Crispr Therapeutics AG with a $70.21 average price target, a 0.16% upside from current levels. In a report released on October 17, Bank of America Securities also reiterated a Buy rating on the stock with a $93.00 price target.

According to TipRanks, Kapoor is a 3-star analyst with an average return of 3.5% and a 43.81% success rate. Kapoor covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Halozyme, and Sarepta Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Crispr Therapeutics AG with a $70.21 average price target, a 0.16% upside from current levels. In a report released on October 17, Bank of America Securities also reiterated a Buy rating on the stock with a $93.00 price target.

### Related Stocks

- [CRSP.US - CRISPR Therap](https://longbridge.com/en/quote/CRSP.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Why CRISPR Therapeutics stock is up today (despite its Q4 earnings miss) | A sales partner offered a ray of hope that this company couldn't for itself. | [Link](https://longbridge.com/en/news/275941492.md) |
| IHI, IHE, ARKG: Specialty Healthcare ETFs Can Help Boost a Portfolio | Specialty healthcare ETFs can enhance investment portfolios by focusing on distinct sectors like pharmaceuticals, medica | [Link](https://longbridge.com/en/news/276080275.md) |
| CRISPR Therapeutics (CRSP): Reassessing Valuation After Casgevy Approvals and Growing 2025 Revenue Expectations | CRISPR Therapeutics (CRSP) gains attention after Casgevy's FDA and EMA approvals, boosting near-term revenue prospects.  | [Link](https://longbridge.com/en/news/268966325.md) |
| Where Were The Job Opportunities In 2025? Where Will They Be In 2026? | In 2025, job growth was minimal, with only Education and Health Care (+697,000 jobs) and Leisure and Hospitality (+119,0 | [Link](https://longbridge.com/en/news/275986113.md) |
| CNL Healthcare Sets NAV, Details Sonida Merger Plans | CNL Healthcare Properties has set an adjusted estimated net asset value (NAV) of $6.90 per share as of November 4, 2025, | [Link](https://longbridge.com/en/news/276164395.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.